Market research
IVX.AU Invion Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 0.11
- Dividend yield
- Not available
- Beta
- 0.45
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000IVX4
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 0.11
- Dividend yield
- Not available
- Beta
- 0.45
About
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Research context
Invion Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IVX.AU discussion.
5 years, 6 months ago
Invion Limited is currently in a long term uptrend where the price is trading 29.5% above its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.3.
Invion Limited's total revenue sank by 32.9% to $1M since the same quarter in the previous year.
Its net income has increased by 27.8% to $-852K since the same quarter in the previous year.
Finally, its free cash flow grew by 85.0% to $-49K since the same quarter in the previous year.
Based on the above factors, Invion Limited gets an overall score of 4/5.